Search
for
Sort by
Research 361–390 of 1000+
- Iron deficiency and hair loss: The jury is still out
- Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
- Characterization of the epidermal-dermal junction in hiPSC-derived skin organoids
- Immunolocalization of junctional proteins in human hairs indicates that the membrane complex stabilizes the inner root sheath while desmosomes contact the companion layer through specific keratins
- CDH3 gene related hypotrichosis and juvenile macular dystrophy – A case with a novel mutation
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Janus kinase inhibitors for alopecia areata
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Frontal fibrosing alopecia, just lichen planopilaris?
- Mechanism of JmjC-containing protein Hairless in the regulation of vitamin D receptor function
- Focal palmoplantar callosities in non-Herlitz junctional epidermolysis bullosa
- Management of the Hirsute Woman
- A review of Janus kinase inhibitor use in scarring alopecia
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Not just thinning: A case of alopecia universalis after mild COVID-19
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
- Scientific precision in titles of research papers published in three dermatology journals
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Primary vitreoretinal lymphoma masquerading as refractory uveitis—just go with the flow
- Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata